Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 10, 2026

Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock?

View original at finance.yahoo.com
Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock? Wells Fargo & Company WFC is slated to report first-quarter 2026 earnings results on April 14, 2026, before market open…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wells Fargo Q1 2026 earnings per share expected to be $1.57, representing 23.6% improvement from prior-year quarter

    60% confidence

  • Wells Fargo Q1 2026 revenues expected to reach $21.73 billion, representing 7.8% year-over-year growth

    60% confidence

  • Net interest income expected to be $12.3 billion in Q1 2026, indicating 6.9% rise from year-ago quarter

    60% confidence

  • Wells Fargo has outpaced earnings consensus estimates in the trailing four quarters with average surprise of 7.53%

    60% confidence

  • Demand for commercial and industrial and consumer loans was impressive in the first two months of Q1 2026, while real estate loan demand was subdued

    60% confidence

  • Mortgage banking revenues expected to be $283 million in Q1 2026, suggesting 14.8% decline from year-ago level

    60% confidence

  • Investment advisory and other asset-based fee revenues expected to be $2.9 billion in Q1 2026, indicating 12.8% year-over-year rise

    60% confidence

Data points we hold from this source

Wells Fargo & Company · mortgage banking revenues283 USD
Wells Fargo & Company · investment advisory fee growth12.8 percent
Wells Fargo & Company · net interest income growth6.9 percent
Wells Fargo & Company · investment advisory fees2.9 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com